Author “Hua Lan” was erroneously omitted as equal contributing author.
The original version of this article has been updated.
Summary
Keywords
advanced or locally advanced lung cancer, disease progression, immune checkpoint inhibitor, immune treatment beyond progression, safety and efficacy
Citation
Frontiers Production Office (2026) Correction: Clinical benefit and safety of immunotherapy beyond progression in advanced and locally advanced lung cancer: a real-world cohort study. Front. Oncol. 16:1897884. doi: 10.3389/fonc.2026.1897884
Received
02 June 2026
Accepted
02 June 2026
Published
13 July 2026
Approved by
Frontiers Editorial Office, Frontiers Media SA, Lausanne, Switzerland
Volume
16 - 2026
Updates
Copyright
© 2026 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.